Pharmacologic therapy of tachyarrhythmias in patients with Wolff-Parkinson-White syndrome.
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000404:Ajmaline / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D001572:Benzofurans / Q000627:therapeutic use*; D004071:Digitalis Glycosides / Q000627:therapeutic use*; D004206:Disopyramide / Q000627:therapeutic use; D016700:Encainide; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy* / Q000209:etiology; D014700:Verapamil / Q000627:therapeutic use; D014927:Wolff-Parkinson-White Syndrome / Q000150:complications*
D000319:Adrenergic beta-Antagonists; D000813:Anilides; D001572:Benzofurans; D004071:Digitalis Glycosides; D000404:Ajmaline; D001073:Aprindine; D008012:Lidocaine; D014700:Verapamil; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide; D000638:Amiodarone; D016700:Encainide